Digital PCR (dPCR) and Real-time PCR (qPCR) Market

The global Digital PCR (dPCR) and Real-time PCR (qPCR) market is projected to reach USD 14.8 billion by 2029 from USD 10.0 billion in 2024, at a CAGR of 8.1% during the forecast period of 2024 to 2029. Growth in the Digital PCR (dPCR) and Real-time PCR (qPCR) market can be attributed to factors such as technological advancements in PCR technologies, increasing incidence of chronic infectious diseases, and increasing adoption of dPCR and qPCR technologies in clinical diagnostics. On the other hand, high device costs associated with dPCR, stringent regulatory compliance issues, and technical limitations of qPCR and dPCR are expected to hinder market growth.

The global Digital PCR (dPCR) and Real-time PCR (qPCR) market is competitive, with Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), and Thermo Fisher Scientific, Inc. (US) accounting for the major market share globally.

To know about the assumptions considered for the study download the pdf brochure

Danaher Corporation (US) has established itself as a leading player in the digital PCR (dPCR) and real-time PCR (qPCR) markets through its innovative technologies and strategic acquisitions. The company's strong portfolio includes high-performance instruments like the QuantStudio and QX200 Droplet Digital PCR Systems, renowned for their precision and reliability in nucleic acid quantification. Danaher's commitment to advancing molecular diagnostics is evident through its continuous investment in research and development, enabling the company to offer state-of-the-art solutions that cater to the evolving needs of clinical and research laboratories. By leveraging its extensive global presence and robust distribution network, Danaher ensures widespread access to its cutting-edge products, thereby maintaining its competitive edge and driving growth in the dPCR and qPCR markets.

F. Hoffmann-La Roche Ltd. (Switzerland) is a key player in the digital PCR (dPCR) and real-time PCR (qPCR) market. Roche’s commitment to innovation is exemplified by its LightCycler and Cobas platforms, which offer high precision, reliability, and user-friendly interfaces. The LightCycler systems, known for their speed and sensitivity, have become industry standards in qPCR, while Roche’s digital PCR solutions provide exceptional accuracy in quantifying nucleic acids, even at low concentrations. Furthermore, Roche recently in November 2023 launched the LightCycler PRO System, which represents their latest advancement in qPCR technology. This system is designed to meet both clinical diagnostic and research needs, offering features such as enhanced temperature uniformity, improved software algorithms, and a user-friendly interface. Thus, innovative products launch keep Roche at the competitive stage in the Digital PCR (dPCR) and Real-time PCR (qPCR) market.

Thermo Fisher Scientific, Inc. (US) is among the top players operating in the Digital PCR (dPCR) and Real-time PCR (qPCR) market addressing the needs  of various end users such as hospital and diagnostic laboratories, CROs, CDMOs,  pharma & biopharma companies and other. The company focuses on strengthening its position in this market by adopting various inorganic and organic growth strategies such as product launches and acquisition and collaboration. For instance, in February 2023, Thermo launched TaqPath, a Real-time PCR kits for detection of infectious diseases in India. Moreover, The company also focuses on research partnerships with leading organizations to strengthen its research and product development capabilities in the field of dPCR and qPCR technologies.

Related Reports:

Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Offering (Product (Reagents & Consumables, Instrument), Software, Services), Application (Clinical (infectious, Oncology), Research, Forensic, Environmental) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]